Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRXBiotechnology
-$0.01 today
- Market cap
- $3.85B
- Beta
- 0.74
- P/E (TTM)
- 17.3
- EPS (TTM)
- $1.81
Volume 0.00M
Average 2.17M
CPRX Account Payables
Amounts the company owes suppliers for goods and services received.
Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 36.1% from a year ago
Account payables stood at $7.15M at the end of Q1 FY2026, down 36.1% from a year earlier and down 36.2% from the prior quarter. Over 3 fiscal years it compounded at +41.2% a year.
Context
- Account payables amounted to 0.6% of total assets at the end of Q1 FY2026, down 0.6 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -36.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 11.2M USD
- Year-over-year change
- -32.5%
- 4-year CAGR
- +41.8%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.2M | -32.5% |
| FY2024 | 2024-12-31 | 16.59M | +12.2% |
| FY2023 | 2023-12-31 | 14.8M | +272.2% |
| FY2022 | 2022-12-31 | 3.98M | +43.6% |
| FY2021 | 2021-12-31 | 2.77M | — |
Account Payables vs competitors
How CPRX compares with its peers on the latest reported figures
- CPRX's Mar 2026 account payables of $7.15M is the 6th highest of the 9 companies compared; the peer median is $12.54M.
- Its year-over-year change of -36.1% is the 8th highest of 9, against a peer median of -4.4%.
- Account payables amounts to 0.6% of total assets for CPRX, versus a peer median of 1.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $20.74M | +17.6% | +60.2% | 2.0% | |
| Mar 2026 | $13.75M | +0.2% | -0.5% | 1.2% | |
| Jun 2026 | $13.1M | +24.1% | +4.3% | 0.9% | |
| Jun 2026 | $12.67M | -34.4% | +58.1% | 1.0% | |
| Jun 2026 | $12.4M | +38.5% | -36.4% | 1.4% | |
| Mar 2026 | $7.15M | -36.1% | +41.2% | 0.6% | |
| Sep 2026 | $6.16M | -8.9% | +37.1% | 1.4% | |
| Jun 2026 | $5.24M | -24.1% | -7.2% | 0.8% | |
| Jun 2026 | $1.07M | -66.3% | +1.9% | 0.2% | |
| Peer median (excluding CPRX) | $12.54M | -4.4% | +3.1% | 1.1% | |
Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 171.45M | 298.4M | 137.64M | 517.55M | 709.17M |
| Short-term Investments | 19.82M | 0 | 0 | 0 | 0 |
| Net Receivables | 6.72M | 10.79M | 53.51M | 65.49M | 128.27M |
| Inventory | 7.87M | 6.81M | 15.64M | 19.54M | 37.17M |
| Other Current Assets | 327K | 0 | 489K | 1.03M | 2.04M |
| Total Current Assets | 210.11M | 320.81M | 219.33M | 623.61M | 894.03M |
| Property, Plant & Equipment (Net) | 3.98M | 3.62M | 3.7M | 3.58M | 2.97M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 32.47M | 194.05M | 156.67M | 131.67M |
| Long-term Investments | 0 | 0 | 16.49M | 21.56M | 22.54M |
| Tax Assets | 23.7M | 18.74M | 36.54M | 45.98M | 55.6M |
| Other Non-current Assets | 9K | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 27.68M | 54.82M | 250.79M | 227.8M | 212.78M |
| Total Assets | 237.79M | 375.63M | 470.11M | 851.41M | 1.11B |
| Account Payables | 2.77M | 3.98M | 14.8M | 16.59M | 11.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 437K |
| Tax Payables | 79K | 8.7M | 729K | 894K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.28M | 5.37M | 51.29M | 11.16M | 122.76M |
| Total Current Liabilities | 27.06M | 57.59M | 76.06M | 120.68M | 147.15M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 2.83M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 14.06M | 2.98M | 315K | 209K |
| Total Non-current Liabilities | 3.89M | 17.62M | 6.17M | 3.1M | 5.39M |
| Total Liabilities | 30.96M | 75.21M | 82.23M | 123.78M | 152.54M |
| Common Stock | 103K | 105K | 107K | 121K | 123K |
| Retained Earnings | (26.31M) | 49.86M | 121.27M | 285.16M | 474.19M |
| Accumulated OCI | (148K) | 24K | 14K | 64K | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 206.83M | 300.42M | 387.88M | 727.63M | 954.27M |
| Total Debt | 4.2M | 3.89M | 3.56M | 3.19M | 2.79M |
| Net Debt | (167.24M) | (294.5M) | (134.08M) | (514.37M) | (706.38M) |
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
Intrinsic Alpha fair value
Locked
Current Price
$31.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.